View Older Stories View More Recent Stories
-
Merck (MRK) Receives Positive EU CHMP Opinion for CAPVAXIVE
-
Merck (MRK) February 7 weekly 99 straddle priced into quarter results
-
Merck (MRK) to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR Early and Move to Final Analysis
-
Merck (MRK) Declares $0.81 Quarterly Dividend; 3.3% Yield
-
Merck (MRK) Announces $10B Share Buyback
-
Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA Plus LENVIMA in Combination with Chemotherapy
-
Merck (MRK) PT Lowered to $122 at Guggenheim
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Merck's (MRK) GARDASIL Receives Expanded Approval for Males in China
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Merck (MRK) Closes Exclusive Global License Agreement for LM-299
-
BMO Capital Downgrades Merck (MRK) to Market Perform
-
Merck (MRK) 'Buys' GLP-1 (HS-10535) From China; Bernstein Reiterates Market Perform Rating
-
Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir
-
BMO Capital on Merck's obesity deal (MRK): 'transaction likely viewed as positive, but Merck would have been better served going after later-stage development'
-
Viking Therapeutics (VKTX) weakness tied to Merck's (MRK) Deal for GLP-1 Receptor Agonist
-
Merck (MRK) Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
-
Bernstein SocGen Group Reiterates Market Perform Rating on Merck (MRK)
-
Merck (MRK) Announces FDA Acceptance of BLA for Clesrovimab
-
Merck (MRK) Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab
-
Merck's (MRK) KEYTRUDA Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment
-
Merck (MRK) Receives Positive EU CHMP Opinion for WELIREG
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Could Moderna stock be due for rally in 2025? Jefferies weighs in
-
Merck (MRK) Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
-
Merck Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025
-
Merck (MRK) and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults
-
HSBC Upgrades Merck (MRK) to Buy
-
Merck (MRK) Granted FDA Breakthrough Therapy Designation to Sacituzumab Tirumotecan
-
Merck (MRK) PT Lowered to $110 at Bernstein SocGen Group as 'Gardasil overhang continues'
-
BMO Capital Reiterates Outperform Rating on Merck (MRK)
-
Merck (MRK) Announces Phase 3 ZENITH Trial Evaluating WINREVAIR Met Primary Endpoint at Interim Analysis
-
Merck's (MRK) WELIREG Approved in China for Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
-
Merck (MRK) Announces Surendralal Karsanbhai Elected to Board of Directors
-
CFRA Upgrades Merck (MRK) to Buy (midday)
-
Merck (MRK) Declares $0.81 Quarterly Dividend; 3.4% Yield
-
JPMorgan Reiterates Overweight Rating on Merck (MRK)
-
Merck (MRK) Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
-
Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemo as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid MPM
-
Merck (MRK) PT Raised to $148 at Jefferies
-
Merck (MRK) call put ratio 1 call to 5.9 puts
-
Merck (MRK) Enters into Exclusive Global License for LM-299
-
Merck (MRK) reports KOSELUGO Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo
-
Merck (MRK) PT Lowered to $136 at BMO Capital
-
Leerink Partners Reiterates Outperform Rating on Merck (MRK)
-
Merck (MRK) Tops Q3 EPS by 7c; narrows guidance range
-
Merck (MRK) call put ratio 2.6 calls to 1 put into quarter results
-
Merck (MRK) call put ratio 2.2 calls to 1 put into quarter results
-
Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA
